ATHEROSCLEROTIC PLAQUES IN HUMAN CORONARY ARTERIES

Authors

  • Dauletbayev B.K. Department of Propaedeutic of Internal Medicine, Faculty of Pediatrics, Candidate of Medical Sciences, Associate Professor Andijan State Medical Institute, Andijan, Uzbekistan. Author

Keywords:

coronary artery disease, cardiovascular disease, lipid accumulation, endothelial dysfunction, vascular inflammation

Abstract

Atherosclerosis, including coronary artery disease (CAD), is one of the most prevalent cardiovascular disorders and is primarily associated with lipid deposition and chronic inflammation within the arterial walls. The progressive development of this condition can lead to serious cardiovascular events, particularly myocardial infarction (MI) and stroke. Although atherosclerosis develops gradually over many years and is more frequently diagnosed in older populations, it continues to represent a major cause of mortality worldwide, despite a reduction in its incidence in certain countries[1-2].The pathological process is characterized by the progressive accumulation and modification of lipids, inflammatory cells, vascular smooth muscle cells, and cellular debris within the arterial intima, beneath the endothelial lining. As atherosclerotic plaques enlarge, they progressively narrow the vascular lumen, potentially reducing blood flow by more than 50%. This impaired circulation may manifest clinically as angina pectoris, especially during physical exertion or emotional stress. In advanced stages, atherosclerotic plaques may become vulnerable and rupture, particularly when they contain substantial lipid deposits and inflammatory components[3]. Plaque rupture in coronary arteries can trigger thrombus formation, resulting in partial or complete arterial occlusion and subsequent myocardial infarction. In some cases, thromboembolic material may enter the systemic circulation and reach cerebral vessels, potentially causing an ischemic stroke.

References

1.Ajoolabady A, Pratico D, Lin L, Mantzoros CS, Bahijri S, Tuomilehto J, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 2024;15:817. doi: 10.1038/s41419-024-07166-8

2.Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–1866.

3.Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. Eur Heart J. 2020;41(24):2313–2330.

4.Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636.

5.Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695.

6.Libby P. Inflammation and the pathogenesis of atherosclerosis. Vasc Pharmacol. 2024;157:107255. doi: 10.1016/j.vph.2023.107255.

7.Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874.

8.Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524–533.

9.Luca AC, David SG, David AG, Țarcă V, Pădureț IA, Mîndru DE, et al. Atherosclerosis from newborn to adult—epidemiology, pathological aspects, and risk factors. Life (Basel). 2023;13(10):2056. doi: 10.3390/life13102056.

10.Tabas I, Bornfeldt KE. Intracellular and intercellular aspects of macrophage immunometabolism in atherosclerosis. Circ Res. 2020;126(9):1209–1227.

Downloads

Published

2026-11-07